Report "The clinical trial protocol: strategy for success"

20.11.2014

 

The report of IPHARMA Chief Operating Officer Natalia Vostokova at the Adam Smith Forum "Clinical Trials in Russia".

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia

30.12.2014

​

The article on the internal results of clinical trial SRX-1374-02 "Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia" has been published in the journal "Diabetes" 2014;(4).

New oral Factor Xa inhibitor TRxl

09.06.2015

 

The advantages of New oral Factor Xa inhibitor TRxl (clinical trial CV-TRX-01) has been presented at the Annual drug discovery summit 2015 in Berlin.

Report "The use of adaptive design in comparison of DPP-4 inhibitors"

17.06.2015

​

The report of IPHARMA Chief Operating Officer Natalia Vostokova at the Global conference DIA 2015 51st Annual Meeting in Washington.

Report "Efficacy and Safety of Gosogliptin as Monotherapy and in Combination with Metformin in Patients with Type 2 Diabetes Mellitus"

05.06.2015

 

The report of IPHARMA Medical director Julia  Trakhtenberg at the International science conference ADA 75th Scientific Sessions in Boston.

PE7/4 Safety and antiviral effect of Elpida (VM-1500), a novel NNRTI (+Truvada) in treatment-naïve HIV-1 infected patients

24.10.2015

 

The results of clinical trial HIV-VM1500-04 Elpida has been presented at AIDS Conference 21-24 October 2015.